These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1867963)

  • 1. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.
    Ward SA; Helsby NA; Skjelbo E; Brøsen K; Gram LF; Breckenridge AM
    Br J Clin Pharmacol; 1991 Jun; 31(6):689-92. PubMed ID: 1867963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
    Brøsen K; Skjelbo E; Flachs H
    Br J Clin Pharmacol; 1993 Aug; 36(2):105-8. PubMed ID: 8398577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.
    Setiabudy R; Kusaka M; Chiba K; Darmansjah I; Ishizaki T
    Br J Clin Pharmacol; 1995 Mar; 39(3):297-303. PubMed ID: 7619672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.
    Hoskins JM; Shenfield GM; Gross AS
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):611-4. PubMed ID: 13680037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans.
    Funck-Brentano C; Bosco O; Jacqz-Aigrain E; Keundjian A; Jaillon P
    Clin Pharmacol Ther; 1992 May; 51(5):507-12. PubMed ID: 1587064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status.
    Kusaka M; Setiabudy R; Chiba K; Ishizaki T
    Am J Trop Med Hyg; 1996 Feb; 54(2):189-96. PubMed ID: 8619446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    Drøhse A; Bathum L; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
    Madsen H; Nielsen KK; Brøsen K
    Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multiple dose pharmacokinetics of proguanil.
    Helsby NA; Edwards G; Breckenridge AM; Ward SA
    Br J Clin Pharmacol; 1993 Jun; 35(6):653-6. PubMed ID: 8329294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil.
    McGready R; Stepniewska K; Seaton E; Cho T; Cho D; Ginsberg A; Edstein MD; Ashley E; Looareesuwan S; White NJ; Nosten F
    Eur J Clin Pharmacol; 2003 Oct; 59(7):553-7. PubMed ID: 12955370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic oxidative metabolism of proguanil in a Nigerian population.
    Bolaji OO; Sadare IO; Babalola CP; Ogunbona FA
    Eur J Clin Pharmacol; 2002 Nov; 58(8):543-5. PubMed ID: 12451432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism.
    Somogyi AA; Reinhard HA; Bochner F
    Br J Clin Pharmacol; 1996 Mar; 41(3):175-9. PubMed ID: 8866915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.
    Helsby NA; Ward SA; Howells RE; Breckenridge AM
    Br J Clin Pharmacol; 1990 Aug; 30(2):287-91. PubMed ID: 2206791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population.
    Basci NE; Bozkurt A; Kortunay S; Isimer A; Sayal A; Kayaalp SO
    Br J Clin Pharmacol; 1996 Dec; 42(6):771-3. PubMed ID: 8971434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
    Skjelbo E; Brøsen K; Hallas J; Gram LF
    Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
    Skjelbo E; Gram LF; Brøsen K
    Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
    Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.
    Wanwimolruk S; Thou MR; Woods DJ
    Br J Clin Pharmacol; 1995 Aug; 40(2):166-9. PubMed ID: 8562301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.